Federal judge says no to patents on cancer genes


On March 29, a federal district court in New York ruled that DNA sequences are not eligible for patent protection under the U.S. patent laws. The ruling stems from an action filed by the Association for Molecular Pathology along with other organizations and individuals, challenging the validity and constitutionality of patents directed to DNA sequences for the BRCA1 and 2 genes as well as methods for using such sequences for diagnostic tests. The BRCA1 and 2 genes are important in identifying a predisposition to breast and ovarian cancers. Myriad Genetics, a co-defendant in the lawsuit and the exclusive licensee of the patents, uses the patented sequences to provide a genetic test for mutations in the BRCA genes.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McAfee & Taft | Attorney Advertising

Written by:


McAfee & Taft on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.